

⁷⁹
76. The combination of two or more antibodies of claim ⁷⁵72 comprising CBH-7 and CBH-4D.

⁸⁰
77. The combination of two or more antibodies of claim ⁷⁵72 comprising CBH-7 and CBH-17.

⁸¹
78. A virus displaying a combination of two antibodies directed to one or more conformational epitopes of E2 protein of Hepatitis C virus.

⁸²
79. The virus of claim ⁸¹78, wherein the antibodies comprise CBH-7 and CBH-4G.

⁸³
80. The virus of claim ⁸¹78, wherein the antibodies comprise CBH-7 and CBH-4D.

⁸⁴
81. The virus of claim ⁸¹78, wherein the antibodies comprise CBH-7 and CBH-17.

⁸⁵
82. A pharmaceutical composition comprising the antibodies of claim ⁷⁵72, ⁷⁶73, ⁷⁷74, ⁷⁸75, ⁷⁹76, or ⁸⁰79 and a pharmaceutically acceptable excipient.

⁸⁶
83. A method of treating a patient infected with HCV, the method comprising steps of:

providing a patient infected with HCV or susceptible to HCV infection; and
administering to the patient the antibodies of claim ⁷⁵72, ⁷⁶73, ⁷⁷74, ⁷⁸75, ⁷⁹76, or ⁸⁰79.

⁸⁷
84. A method of treating a patient exposed to HCV, the method comprising steps of:

providing a patient exposed to HCV; and
administering to the patient the antibody of claim ⁷⁵72, ⁷⁶73, ⁷⁷74, ⁷⁸75, ⁷⁹76, or ⁸⁰79.

⁸⁸
85. A vaccine comprising a peptide fragment of HCV E2 that contains epitopes recognized by the two or more antibodies of claim ⁷⁵72, ⁷⁶73, or ⁷⁷74.

⁸⁹
86. A vaccine comprising a peptide fragment of HCV E2 that contains one or more epitopes recognized by two human monoclonal antibodies selected from the group consisting of CBH-7 and CBH-4D, CBH-7 and CBH-4G, or CBH-7 and CBH-17.